Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0D4UT
|
||||
| Former ID |
DIB016276
|
||||
| Drug Name |
GSK2849330
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Cancer [ICD9: 140-229; ICD10:C00-C96] | Phase 1 | [1] | ||
| Company |
Glaxosmithkline
|
||||
| Target and Pathway | |||||
| Target(s) | Receptor protein-tyrosine kinase erbB-3 | Target Info | [2] | ||
| KEGG Pathway | ErbB signaling pathway | ||||
| Calcium signaling pathway | |||||
| Endocytosis | |||||
| Proteoglycans in cancer | |||||
| MicroRNAs in cancer | |||||
| NetPath Pathway | TNFalpha Signaling Pathway | ||||
| PANTHER Pathway | Cadherin signaling pathway | ||||
| EGF receptor signaling pathway | |||||
| Pathway Interaction Database | ErbB2/ErbB3 signaling events | ||||
| ErbB receptor signaling network | |||||
| a6b1 and a6b4 Integrin signaling | |||||
| WikiPathways | ErbB Signaling Pathway | ||||
| Apoptosis-related network due to altered Notch3 in ovarian cancer | |||||
| Signaling Pathways in Glioblastoma | |||||
| miR-targeted genes in muscle cell - TarBase | |||||
| Heart Development | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01966445) Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors. U.S. National Institutes of Health. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1798). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.